UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): August 15, 2007
PFIZER INC.
(Exact
name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of
incorporation)
1-3619
(Commission File Number)
13-5315170
(I.R.S. Employer Identification
No.)
235 East 42nd Street, New York, New
York 10017
(Address of
principal executive offices) (zip code)
(212) 573-2323
(Registrant's telephone
number)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the obligation of the registrant
under any of the following provisions:
[ ] Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other
Events
Exhibit 100 to this Current Report on Form 8-K
contains documents formatted in XBRL (eXtensible Business Reporting Language)
with information from Pfizer Inc.'s Quarterly Report on Form 10-Q for the
quarter ended July 1, 2007, filed with the Securities and Exchange
Commission (SEC) on August 6, 2007. The information formatted in XBRL includes
the (i) Condensed Consolidated Statements of Income for the three months and six months ended July